. Author manuscript; available in PMC: 2012 May 16.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 May 1;57(1):46–50. doi: 10.1097/QAI.0b013e318214fe27

Table 1.

Clinical characteristics and coreceptor usage of women infected with HIV-1C

	Availability for testing of coreceptor usage				Stratified by coreceptor usage
Baseline characteristics	total	available	not available	P	total	R5	DM	P
Maternal age (n)	206	153	53	0.49	148	126	22	0.03
median age		28.3	29.4			28.1	33.1
Baseline CD4 cell count (n)	206	153	53	0.8	148	126	22	0.08
median cells/mm³ (IQR)		130 (95–171)	139 (94–167)			141 (103–172)	121 (56–157)
Baseline HIV-1 RNA (n)	203	151	52	0.01	147	125	22	0.94
median logi₁₀copies/ml (IQR)		5.0 (4.5–5.4)	4.6 (3.9–5.2)			5.0 (4.5–5.4)	5.2 (4.4–5.4)
Time to start of ART (n)	166	119	47	<0.001	116	99	17	0.25
months (IQR)		7.0 (2.1–13.7)	2.2 (−0.3–5.8)			7.2 (2.5–14.3)	3.9 (1.1–10.7)
ART initiation (n)	206	153	53	0.11	148	126	22	1
yes (%)		119 (78)	47 (89)			99 (79)	17 (77)
Maternal death (n)	206	153	53	0.77	148	126	22	1
yes (%)		12 (8)	5 (9)			10 (8)	1 (5)
HIV transmission to infant (n)	206	153	53	0.65	148	126	22	1
yes (%)		22 (14)	6 (11)			19 (15)	3 (14)